Answers are grounded in this paper and cite their sources.
This article reviews the impact of continuous erythropoietin receptor activators on anemia management in hemodialysis patients, highlighting acceptance barriers.
This article reviews the role of the Continuous Erythropoetin Receptor Activators (CERAs) in the management of anemia in the dialysis population. Despite the convenience of once per month dosage frequency instead of the twice per week conventional erythropoetin stimulators, CERAs have struggled to achieve universal acceptance. This article sheds light on the reasons and fairness of this choice.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: